한글목차

고셰병의 유병률은 주요 7개국 시장의 인구 증가에 따라 AGR 0.39%로 꾸준히 증가하고 있습니다. 현재 1형 고셰병과 3형 고셰병 치료제로 시판되고 있는 ERT와 SRT(세레자임, VPRIV, 엘레리소, 셀데르가, 자베스카)가 주류를 이루고 있습니다.

2형 고셰병과 3형 고셰병 환자가 보이는 신경장애 증상에 대한 효과적인 치료제가 없는 등 고셰병 분야에는 몇 가지 미충족 수요가 존재합니다.

고셰병의 R&D 파이프라인에는 유전자 치료제와 최초의 뇌투과성 SRT가 될 것으로 기대되는 벤글루스타트 말산염과 같은 몇 가지 혁신적인 제품이 있습니다. 고셰병 환자 수의 점진적인 증가와 진단 접근법의 개선으로 예측 기간 동안 안정적인 시장 성장이 예상됩니다.

본 보고서는 주요 7개국(미국, 유럽 5개국(프랑스, 독일, 이탈리아, 스페인, 영국) 및 이스라엘)의 고셰병 시장을 조사했으며, 시장 개요와 함께 2022-2032년까지의 시장 예측, 경쟁 상황 등을 정리하여 전해드립니다.

목차

제1장 서문

제2장 주요 요약

제3장 질병 개요

• 고셰병 개요
• 고셰병 SWOT 분석
• 고셰병 분류

제4장 역학

제5장 현재 치료 선택사항

• 치료 패러다임
• 현재 치료 선택사항
• 제품 개요 : 효소보충요법(Cerezyme, VPRIV, Elelyso)
• 제품 프로파일 : 기질감소요법(Zavesca, Cerdelga)
• 현재 치료 선택사항 - KOL의 관점

제6장 미충족 수요와 기회

• 고셰병의 미충족 수요
• 신경장애 요법의 현저한 부족
• 시판 치료법은 고액
• 불편한 치료 옵션
• 조기 진단과 스크리닝이 필요

제7장 연구개발 전략

• 고셰병의 거래 동향
• 고셰병의 임상시험 설계 동향

제8장 파이프라인 평가

제9장 시장 전망

• 고셰병 시장 예측
• 시장 성장 촉진요인과 억제요인

제10장 부록

제11장 문의

영문목차

Abstract

The prevalence of GD is increasing at a steady rate, in line with population growth in the 7MM, at an AGR of 0.39%.

Currently, the marketed treatment regimen for Type 1 GD and Type 3 GD is dominated by ERTs and SRTs (Cerezyme, VPRIV, Elelyso, Cerdelga, Zavesca).

There are several unmet needs in the GD landscape, including the lack of effective therapies for treating the neuropathic manifestations presented by Type 2 GD and Type 3 GD patients.

The GD R&D pipeline offers some innovative products, including gene therapy and venglustat malate, which is expected to be the first brain-penetrant SRT.

Steady market growth is expected throughout the forecast period as the GD population slowly increases and diagnostic approaches improve.

Key Highlights

Report deliverables include a PowerPoint report and Excel-based forecast model.

Forecast includes 7MM: US, 5EU (France, Germany, Italy, Spain and the UK) and Israel.

Forecasts cover 2022-2032.

Scope

• Overview of GD, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized GD therapeutics market revenue in 7MM (US, 5EU and Israel), annual cost of therapy and treatment usage pattern in 2022 and forecast for 10 years to 2032.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the GD therapeutics market.
• Pipeline analysis, comprehensive data assessing emerging trends and mechanisms of action under development for GD treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the 7MM GD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the GD therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the GD therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1. Preface

• 1.1. Contents
• 1.2. Abbreviations
• 1.3. Related Reports

2. Executive Summary

3. Disease Overview

• 3.1. Overview of Gaucher Disease
• 3.2. Gaucher Disease SWOT Analysis
• 3.3. Classification of Gaucher Disease

4. Epidemiology

• 4.1. Diagnosed Prevalent Cases of GD
• 4.2. Diagnosed Prevalent Cases of GD by Type
• 4.3. Sources and Methodology for GD Prevalence
• 4.4. Sources and Methodology for GD

5. Current Treatment Options

• 5.1. Treatment Paradigm
• 5.2. Current Treatment Options
• 5.3. Product Profile: Enzyme Replacement Therapy (Cerezyme, VPRIV, Elelyso)
• 5.4. Product Profile: Substrate Reduction Therapy (Zavesca, Cerdelga)
• 5.5. Current Treatment Options - KOL Perspective

6. Unmet Needs and Opportunities

• 6.1. Unmet Needs in Gaucher Disease
• 6.2. Significant Lack of Neuropathic Therapies
• 6.3. Marketed Therapies are Highly Expensive
• 6.4. Inconvenient Treatment Options
• 6.5. Early Diagnosis and Screening is Required

7. R&D Strategies

• 7.1. Trends in Deal-Making in Gaucher Disease
• 7.2. Trends in Clinical Trial Design in Gaucher Disease

8. Pipeline Assessment

• 8.1. Gaucher Disease Pipeline Overview
• 8.2. Late-Stage Pipeline Agents for Gaucher Disease
• 8.3. Product Profile: Sanofi's Venglustat malate
• 8.4. Product Profile: Sanofi's Eliglustat tartrate
• 8.5. Product Profile: SZMC-Takeda's Ambroxol
• 8.6. Gaucher Disease Clinical Trials Overview

9. Market Outlook

• 9.1. Gaucher Disease Market Forecast
• 9.2. Market Drivers and Barriers

10. Appendix

• 10.1. Bibliography
• 10.2. About the Authors

11. Contact Us